Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 25 January 2013 | By Alexander Gaffney, RAC,
The European Medicines Agency's (EMA) has released a revised version of its procedural advice for sponsors of medicinal products using the centralised procedure, part of an ongoing series of revisions to one of its key regulatory documents.
The centralised procedure, established in EC No. 726/2004, is intended to allow application sponsors to obtain a single marketing authorization from EMA that is accepted throughout the EU.
With the passage of additional legislation, the procedure continues to grow in complexity and requirements, and EMA regulatory updates one document, pre-authorisation procedural advice for users of the centralised procedure, to assist sponsors on how best to navigate its considerable complexities.
Among the 54 questions it answers-ranging from the conduct of pre-submission meetings to eligibility standards-are two newly revised sections.
Section four explains how products are to be named, and whether the branded ('invented') name of the product is acceptable from a public health standpoint. The naming of drugs is important to regulators because ones that are too similar or are easily confused may cause public health problems. Thus, a pain pill by the name of "Paintera" (painpillus genericum) might not be approved based on its similarity to similarly named hypothetical drugs, "Paintella" or "Paintena" based on, respectively, how similar the names sound and look.
EMA added that companies must also be sure that the names of their products are not liable to be confused with the scientific name of a product or with an already trademarked name.
Such products are reviewed by the Name Review Group (NRG), which determines if a product's proposed name is acceptable for public use. Approved names are able to be changed after marketing authorization is granted, but must undergo a new name review after the submission of a Type IAIN variation notification to EMA.
Section 53, meanwhile, is concerned with marketing authorization of centrally authorized products in Norway, Iceland and Liechtenstein-none of which are formal members of the EU. While they are signatories to the European Economic Area agreement, meaning that they are parties to the centralised procedure, decisions by the European Commission (EC) are not legally binding in Norway or Iceland. In those states, decisions on national authorization must be done on a case-by-case basis, though the countries will render a decision within 30 days of the EC's decision.
Tags: Centralized Procedure, Centralised Procedure
Regulatory Focus newsletters
All the biggest regulatory news and happenings.